Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Target-ABC
2015-003399-58Phase 4Terminated
- Sponsor
- COP:TRIN Region Hovedstaden (Gentofte hospital)
- Start
- Jan 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ciprofloxacin and piperacillin + tazobactam in chronic obstructive pulmonary disease (COPD), bronchiectasis, asthma and 1 more (2 arms), sponsored by COP:TRIN Region Hovedstaden (Gentofte hospital). Primary endpoint: Time to exacerbation requiring systemic therapy or death. Started Jan 2016; status: terminated.
02
Drugs
ciprofloxacinpiperacillin + tazobactam
03
Conditions
chronic obstructive pulmonary disease (COPD)bronchiectasisasthmaAirways Infection
Beyond the preview
Go deeper on 2015-003399-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003399-58.